ArticleInflammatory bowel diseases2018
Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease.
Article in Inflammatory bowel diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- High thrombin activity associated with crohn's disease induces microbiota pathogenicity contributing to mucosal inflammation.Gut microbes · 2026Article
- Integrative multi-omics analysis unravels the metabolic landscape and reveals serum biomarkers for early diagnosis of hyperuricemia.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Working together: gut microbe-microbe interactions shape host inflammation.Infection and immunity · 2025Review
- Pathogenicity of commensal gut biofilm in prefrail aging.NPJ biofilms and microbiomes · 2025Article
- Organosilicone double-long-chain diquaternary ammonium salt acts as a biofilm scavenger to ameliorate colitis induced by dextran sulfate sodium salt.Frontiers in immunology · 2025Article
- Mesalazine: a novel therapeutic agent for periodontitis via regulation of periodontal microbiota and inhibitingFrontiers in microbiology · 2025Article
- Gut Microbial Dysbiosis and Implications in Solid Organ Transplantation.Biomedicines · 2024Review
- Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities.Clinical microbiology reviews · 2024Review
- Aerobic iron-oxidizing bacteria secrete metabolites that markedly impede abiotic iron oxidation.PNAS nexus · 2023Article
- A thermo-resistant and RNase-sensitive cargo fromJournal of extracellular biology · 2023Article
- Modulating the Microbiome for Crohn's Disease Treatment.Gastroenterology · 2023Review
- Gut microbiota biofilms: From regulatory mechanisms to therapeutic targets.The Journal of experimental medicine · 2023Article
- Appendix and Ulcerative Colitis: a Key to Explaining the Pathogenesis and Directing Novel Therapies?Inflammatory bowel diseases · 2023Review
- Leaky Gut in IBD: Intestinal Barrier-Gut Microbiota Interaction.Journal of microbiology and biotechnology · 2022Review
- Effects of Hydrogen Sulfide on the Microbiome: From Toxicity to Therapy.Antioxidants & redox signaling · 2022Review
- Current and future aspects of IBD research and treatment: The 2022 perspective.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Review
- Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet?Toxins · 2021Review
- Shining a Light on Colibactin Biology.Toxins · 2021Review
- Gastrointestinal biofilms in health and disease.Nature reviews. Gastroenterology & hepatology · 2021Review
- Microbial adaptation to the healthy and inflamed gut environments.Gut microbes · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Significant alterations of intestinal microbiota and anemia are hallmarks of inflammatory bowel disease (IBD). It is widely accepted that iron is a key nutrient for pathogenic bacteria, but little is known about its impact on microbiota associated with IBD. We used a model device to grow human mucosa-associated microbiota in its physiological anaerobic biofilm phenotype. Compared to microbiota from healthy donors, microbiota from IBD patients generate biofilms ex vivo that were larger in size and cell numbers, contained higher intracellular iron concentrations, and exhibited heightened virulence in a model of human intestinal epithelia in vitro and in the nematode Caenorhabditis elegans. We also describe an unexpected iron-scavenging property for an experimental hydrogen sulfide-releasing derivative of mesalamine. The findings demonstrate that this new drug reduces the virulence of IBD microbiota biofilms through a direct reduction of microbial iron intake and without affecting bacteria survival or species composition within the microbiota. Metabolomic analyses indicate that this drug reduces the intake of purine nucleosides (guanosine), increases the secretion of metabolite markers of purine catabolism (urate and hypoxanthine), and reduces the secretion of uracil (a pyrimidine nucleobase) in complex multispecies human biofilms. These findings demonstrate a new pathogenic mechanism for dysbiotic microbiota in IBD and characterize a novel mode of action for a class of mesalamine derivatives. Together, these observations pave the way towards a new therapeutic strategy for treatment of patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.